THE ULTIMATE GUIDE TO PICEATANNOL 4'-O-?-D-GLUCOPYRANOSIDE

All enrolled clients who obtained at the least a single dose of zosuquidar or placebo for the duration of induction had been monitored for the event of adverse gatherings (439 patients, 219 on zosuquidar and 210 on placebo). The commonest adverse functions were connected with the duration of prolonged and major myelosuppression as is expected with